QSAR application of natural therapeutics inhibitors against Alzheimer’s disease through in-silico virtual-screening, docking-simulation, molecular dynamics, and pharmacokinetic prediction analysis

Abstract

Alzheimer’s disease (AD) is a brain disorder that is known to be one of the deadliest diseases affecting humanity, especially adults from the age of sixty (60) years and above. It mostly affects thinking ability, behaviour and social skills, eventually, AD causes the brain to shrink and brain cells to die. To curb the menace of this disease, virtual screening of potent, non-toxic hybrid natural therapeutic inhibitors was performed on some inhibitors of AD. We performed simulations on the screened compounds and predicted their druggability. A model with satisfactory statistical properties was developed in this study. The ligands underwent molecular docking, C-19 exhibited the highest docked score of -12.8 kcal/mol against the target, while the referenced compound (harmine) indicated the lowest docked score of -8.2 kcal/mol. The docked complex was validated using molecular dynamic simulations. Trajectory plots of C-19 were obtained and found to be stable. C-19 was stable during the 100 ns intervals which implies that the compounds were better than the referenced compound. In addition, ADMET has demonstrated that these ligands have good pharmacokinetic properties. All the evaluations were more comprehensive and beneficial to researchers and the medical community as outstanding results were obtained.

Keywords

DYRK1A / Alzheimer’s disease / Molecular dynamics / Energy of interaction / ADMET / Docking

References

[1] Behl T, Kaur G, Sehgal A, et al. The multifaceted role of matrix metalloproteinases in neurodegenerative diseases: pathophysiological and therapeutic perspectives. Int J Mol Sci. 2021;22(3):1413.

[2] Elfawy HA, Das B. Crosstalk between mitochondrial dysfunction, oxidative stress, and age-related neurodegenerative disease: etiologies and therapeutic strategies. Life Sci. 2019;218:165–184.

[3] Ajala A, Uzairu A, Shallangwa GA, Abechi SE. Computational and pharmacokinetics studies of 1, 3-dimethylbenzimidazolinone analogues of new proposed agent against Alzheimer’s disease. Beni-Suef University Journal of Basic and Applied Sciences. 2022; 11(1):1–19.

[4] Abduljelil A, Uzairu A, Shallangwa GA, Abechi SE. Virtual screening, molecular docking simulation and ADMET prediction of some selected natural products as potential inhibitors of NLRP3 inflammasomes as drug candidates for Alzheimer disease. Biocatal Agric Biotechnol. 2023:102615.

[5] Weithorn LA. Psychological distress, mental disorder, and assessment of decisionmaking capacity under US medical aid in dying statutes. Hastings LJ. 2019; 71:637.

[6] Calhoun A, King C, Khoury R, Grossberg GT. An evaluation of memantine ER+ donepezil for the treatment of Alzheimer’s disease. Expet Opin Pharmacother. 2018; 19(15):1711–1717.

[7] Hung A, Schneider M, Lopez MH, McClellan M. Preclinical Alzheimer disease drug development: early considerations based on phase 3 clinical trials. Journal of Managed Care and Specialty Pharmacy. 2020;26(7):888–900.

[8] Ferreira JP, Albuquerque HM, Cardoso SM, Silva AM, Silva VL. Dual-target compounds for Alzheimer’s disease: natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR). Eur J Med Chem. 2021;221: 113492.

[9] Xu M, Peng Y, Zhu L, Wang S, Ji J, Rakesh KP. Triazole derivatives as inhibitors of Alzheimer’s disease: current developments and structure-activity relationships. Eur J Med Chem. 2019;180:656–672.

[10] Haghighijoo Z, Zamani L, Moosavi F, Emami S. Therapeutic potential of quinazoline derivatives for Alzheimer’s disease: a comprehensive review. Eur J Med Chem. 2022; 227:113949.

[11] Pathak A, Rohilla A, Gupta T, et al. DYRK1A kinase inhibition with emphasis on neurodegeneration: a comprehensive evolution story-cum-perspective. Eur J Med Chem. 2018;158:559–592.

[12] Pandey M, Fernandez M, Gentile F, et al. The transformational role of GPU computing and deep learning in drug discovery. Nat Mach Intell. 2022;4(3):211–221.

[13] Schaduangrat N, Lampa S, Simeon S, Gleeson MP, Spjuth O, Nantasenamat C. Towards reproducible computational drug discovery. J Cheminf. 2020;12:1–30.

[14] Sharma S, Bhatia V. Phytochemicals for drug discovery in Alzheimer’s disease: in silico advances. Curr Pharmaceut Des. 2021;27(25):2848–2860.

[15] Job N, Thimmakondu VS, Thirumoorthy K. In silico drug design and analysis of dual amyloid-beta and tau protein-aggregation inhibitors for alzheimer’s disease treatment. Molecules. 2023;28(3):1388.

[16] Juandó-Prats C, James E, Bilder DA, et al. DRAVET ENGAGE. Parent caregivers of children with Dravet syndrome: perspectives, needs, and opportunities for clinical research. Epilepsy Behav. 2021;122:108198.

[17] Mansouri K, Grulke CM, Judson RS, Williams AJ. OPERA models for predicting physicochemical properties and environmental fate endpoints. J Cheminf. 2018; 10(1):1–19.

[18] Ejeh S, Uzairu A, Shallangwa GA, Abechi SE. Computational insight to design new potential hepatitis C virus NS5B polymerase inhibitors with drug-likeness and pharmacokinetic ADMET parameters predictions. Future Journal of Pharmaceutical Sciences. 2021;7:1–13.

[19] Ajala A, Uzairu A, Shallangwa GA, Stephen AE. QSAR, molecular docking, dynamic simulation and kinetic study of monoamine oxidase B inhibitors as anti-alzheimer agent. Chemistry Africa. 2022:1–14.

[20] Wilson BD, Hariri AA, Thompson IA, Eisenstein M, Soh HT. Independent control of the thermodynamic and kinetic properties of aptamer switches. Nat Commun. 2019; 10(1):5079.

[21] Dimier N, Delmar P, Ward C, et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood, The Journal of the American Society of Hematology. 2018;131(9):955–962.

[22] Peter SC, Dhanjal JK, Malik V, et al. In: Ranganathan S, Grib-skov M, Nakai K, Schönbach C, eds. Encyclopedia of Bioinformatics and Computational Biology. 2019: 661–676.

[23] Patil SM, Maruthi KR, Bajpe SN, et al. Comparative molecular docking and simulation analysis of molnupiravir and remdesivir with SARS-CoV-2 RNA dependent RNA polymerase (RdRp). Bioinformation. 2021;17(11):932.

[24] Fukuda T, Ishiyama T, Katagiri T, et al. Discovery of DS42450411 as a potent orally active hepcidin production inhibitor: design and optimization of novel 4-aminopyrimidine derivatives. Bioorg Med Chem Lett. 2018;28(20):3333–3337.

[25] Martiz RM, Patil SM, Abdulaziz M, et al. Defining the role of isoeugenol from ocimum tenuiflorum against diabetes mellitus-linked alzheimer’s disease through network pharmacology and computational methods. Molecules. 2022;27(8):2398.

[26] Gurupadaswamy HD, Ranganatha VL, Ramu R, Patil SM, Khanum SA. Competent synthesis of biaryl analogs via asymmetric Suzuki–Miyaura cross-coupling for the development of anti-inflammatory and analgesic agents. J Iran Chem Soc. 2022;19(6): 2421–2436.

[27] Maradesha T, Patil SM, Al-Mutairi KA, Ramu R, Madhunapantula SV, Alqadi T. Inhibitory effect of polyphenols from the whole green jackfruit flour against α-glucosidase, α-amylase, aldose reductase and glycation at multiple stages and their interaction: inhibition kinetics and molecular simulations. Molecules. 2022;27(6): 1888.

[28] Patil SM, Martiz RM, Satish AM, et al. Discovery of novel coumarin derivatives as potential dual inhibitors against α-glucosidase and α-amylase for the management of post-prandial hyperglycemia via molecular modelling approaches. Molecules. 2022; 27(12):3888.

[29] Ganavi D, Ramu R, Kumar V, et al. In vitro and in silico studies of fluorinated 2, 3-disubstituted thiazolidinone-pyrazoles as potential α-amylase inhibitors and antioxidant agents. Arch Pharmazie. 2022;355(3):2100342.

[30] Jyothi M, Khamees HA, Patil SM, Ramu R, Khanum SA. Microwave-assisted synthesis, characterization, docking studies and molecular dynamic of some novel phenyl thiazole analogs as xanthine oxidase inhibitor. J Iran Chem Soc. 2022:1–15.

[31] Prabhakaran S, Nivetha N, Patil SM, et al. One-pot three-component synthesis of novel phenyl-pyrano-thiazol-2-one derivatives and their anti-diabetic activity studies. Results in Chemistry. 2022;4:100439.

[32] Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):1–13.

[33] Lipinski CA. Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv Drug Deliv Rev. 2016;101:34–41.

[34] Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Combin Chem. 1999;1(1):55–68.

[35] Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–2623.

[36] Egan WJ, Merz KM, Baldwin JJ. Prediction of drug absorption using multivariate statistics. J Med Chem. 2000;43(21):3867–3877.

[37] Muegge I, Heald SL, Brittelli D. Simple selection criteria for drug-like chemical matter. J Med Chem. 2001;44(12):1841–1846.

[38] Abdullahi M, Adeniji SE. In-silico molecular docking and ADME/pharmacokinetic prediction studies of some novel carboxamide derivatives as anti-tubercular agents. Chemistry Africa. 2020;3(4):989–1000.

[39] ElMchichi L, Belhassan A, Lakhlifi T, Bouachrine M. 3D-QSAR study of the chalcone derivatives as anticancer agents. J Chem. 2020;2020:1–12.

[40] Floresta G, Gentile D, Perrini G, Patamia V, Rescifina A. Computational tools in the discovery of FABP4 ligands: a statistical and molecular modeling approach. Mar Drugs. 2019;17(11):624.

[41] Adamski A, Kruszka D, Dutkiewicz Z, Kubicki M, Gorczyński A, Patroniak V. Novel family of fused tricyclic (1, 4) diazepines: design, synthesis, crystal structures and molecular docking studies. Tetrahedron. 2017;73(24):3377–3386.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.